前往化源商城
入驻化源商城

品牌现货直购
供应商:我要出现这里


查看所有供应商和价格请点击:

1217819-15-2生产厂家

1217819-15-2价格

1217819-15-2

1217819-15-2结构式
1217819-15-2结构式
  • 常用中文名:Tipranavir-d4
  • 常用英文名:Tipranavir-d4
  • CAS号:1217819-15-2
  • 分子式:C31H33F3N2O5S
  • 分子量:602.664
  • 相关类别: 信号通路 抗感染 HIV
  • 发布时间:2021-06-04 10:47:33
  • 更新时间:2024-04-06 13:55:46
  • Tipranavir-d4(PNU-140690-d4)是氘标记的Tipranavir。Tipranavir(PNU-140690)抑制HIV-1蛋白酶的酶活性和二聚化,对IC50s为66-410 nM的耐多蛋白酶抑制剂(PI)的HIV-1分离株发挥有效活性[1][2]。蒂普拉那韦抑制SARS-CoV-2 3CLpro活性[3]。

化源商城直购

中文名 替拉那韦-D4
英文名 Tipranavir-d4
英文别名 N-(3-{(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phényléthyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phényl)-5-(trifluorométhyl)pyridine-2-sulfonamide
2-Pyridinesulfonamide, N-(3-((1R)-1-((6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl)propyl)phenyl)-5-(trifluoromethyl)-
N-(3-{(1R)-1-[(6R)-4-Hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide
ZZT404XD09
2-Pyridinesulfonamide, N-[3-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-
N-[3-[(1R)-1-[(6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide
Tipranavir
MFCD00949098
N-(3-{(1R)-1-[(6R)-4-Hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phenyl)-5-(trifluormethyl)pyridin-2-sulfonamid
N-(3-{(1R)-1-[(6R)-4-Hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide
N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE
PNU 140690E
[R-(R*,R*)]-N-[3-[1-[5,6-Dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide
aptivus
描述 Tipranavir-d4(PNU-140690-d4)是氘标记的Tipranavir。Tipranavir(PNU-140690)抑制HIV-1蛋白酶的酶活性和二聚化,对IC50s为66-410 nM的耐多蛋白酶抑制剂(PI)的HIV-1分离株发挥有效活性[1][2]。蒂普拉那韦抑制SARS-CoV-2 3CLpro活性[3]。
相关类别
体外研究 氢、碳和其他元素的稳定重同位素已被纳入药物分子,主要作为药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注[1]。
参考文献

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Aoki M, et al. Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1. J Virol. 2012 Dec;86(24):13384-96.

[3]. Li F, et al. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8.

[4]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.

密度 1.3±0.1 g/cm3
沸点 712.3±70.0 °C at 760 mmHg
分子式 C31H33F3N2O5S
分子量 602.664
闪点 384.6±35.7 °C
精确质量 602.206238
LogP 7.20
蒸汽压 0.0±2.4 mmHg at 25°C
折射率 1.579
储存条件 -20°C,干燥,密封
危害码 (欧洲) Xi